An analysis indicated that HCC patients within the high-risk group manifested a greater prevalence of TP53 mutations and a poorer prognosis, consistent with earlier studies, such as those conducted by Tang et al. The conclusion drawn was that an unfavorable prognosis is likely for patients categorized as high-risk. The gene discussed is TP53; the disease is hepatocellular carcinoma.